NUCOLL43 Cell Line
Invented by Prof Nicola Curtin from University of Newcastle upon Tyne
Invented at Northern Institute For Cancer Research, Newcastle University
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153716 |
| Parental Line | Clear cell adenocarcinoma of gynecological origin |
| Synonyms | O-CCC, ovarian clear cell carcinoma, HGSC, high grade ovarian cancer, TP53, CA125, LOH, loss of heterozygosity |
| Host | Human |
| Tissue | Ovary |
| Disease Keywords | Ovarian clear cell carcinoma |
| Model | Cancer Model |
| Relevance |
Ovarian cancer is a significant cause of death in women worldwide with the majority of ovarian cancers forming in women under the age of 65. Due to late stage diagnosis and a lack of reliable screening tests, survival rates after 5 years are below 50% in developing counties. Ovarian cancer can spread to tissues in close proximity to the ovaries, including the lining of the abdomen, lungs, lymph nodes and liver. Ovarian cancer has a number of histological subtypes and ovarian clear cell carcinomas generally respond poorly to chemotherapy |
| Conditional | No |
| Research Area | Cancer, Cell Cycle, Gene Expression, Genetic Studies Tools, Reproductive Biology |
| Growth/Phenotype Keywords | Doubling time approximately 45 hours |
| Recommended Growing Conditions | RPMI-1640 media supplemented with 20% FBS and cultured at 37C in 5% CO2. |
| Notes |
NUCOLL43 was established from ascitic fluid from a female 57 year old white British patient without artifical immortalisation. Cells display a complete loss of TP53 expression and function despite having no loss of chromosome 17p and show highly similar pan-genomic similarity to the original patient tumor. Like the original tumor, the cells also expressed epithelial and mesenchymal characteristics. NUCOLL43 cells poses a very high degree of loss of heterozygosity which affected 85% of the genome. NUCOLL43 cells are resistant to cisplatin and rucaparib, but sensitive to paclitaxel, camptothecin and NVP-BEZ 235. |
References: 2 entries
Franklin et al. 2018. Cancer Med. :. PMID: 30109783.
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
Europe PMC ID: 30109783
Add a reference
References: 2 entries
Franklin et al. 2018. Cancer Med. :. PMID: 30109783.
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
Add a reference
